Scripps

My videos
Greatest impact of immune checkpoint inhibitors in hematologic malignancies

Greatest impact of immune checkpoint inhibitors in hemato...
Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.


www.scrippshealth.org/cancer
530 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies
Management of hematologic and solid tumor malignancies wi...
476 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Most common adverse events for PD-1 and PD-L1 monoclonal antibodies
Most common adverse events for PD-1 and PD-L1 monoclonal...
423 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Real world experience with the novel immune checkpoint inhibitors
Real world experience with the novel immune checkpoint in...
375 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Using Biomarkers in Immunotherapy in Head and Neck Cancer.
Using Biomarkers in Immunotherapy in Head and Neck Cancer.
295 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab and nivolumab Immunotherapies Show Efficacy in Head and Neck Cancer
Pembrolizumab and nivolumab Immunotherapies Show Efficacy...
440 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy is well tolerated in Head and Neck Cancer
Immunotherapy is well tolerated in Head and Neck Cancer
406 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy and future use of combination treatment in Head and Neck Cancer
Immunotherapy and future use of combination treatment in ...
489 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax in the management of CLL and where in the therapeutic algorithm it should play a role
Venetoclax in the management of CLL and where in the ther...
288 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
eferred treatment regimen for patients who fail frontline therapy in CLL
eferred treatment regimen for patients who fail frontline...
376 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab
Preferred salvage regimens for Ibrutinib and Idelalisib-R...
288 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Preferred frontline regimen for new CLL patients greater than 70 years
Preferred frontline regimen for new CLL patients greater ...
350 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting
How to decide between Ibrutinib and Idelalisib-Rituximab ...
597 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
FCR produces better and longer progression free survival than BR
FCR produces better and longer progression free survival ...
240 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Duvelisib and other PI3K inhibitors in CLL
Duvelisib and other PI3K inhibitors in CLL
231 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Acalabrutinib, ONO-4059 and other novel BTK inhibitors in CLL
Acalabrutinib, ONO-4059 and other novel BTK inhibitors in...
419 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Future of Immunotherapy new developments and new clinical trials
The Future of Immunotherapy new developments and new clin...
887 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy and finding the correct biomarkers
Immunotherapy and finding the correct biomarkers
321 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immune related adverse events
Immune related adverse events
382 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Indications for systemic therapy of Waldenstroms Macroglobulinemia
Indications for systemic therapy of Waldenstroms Macroglo...
264 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Standard of care options for frontline therapy of Waldenstroms Macroglobulinemia
Standard of care options for frontline therapy of Waldens...
488 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Roles of proteasome inhibitors and immunomodulatory agents in Waldenstroms Macroglobulinemia
Roles of proteasome inhibitors and immunomodulatory agent...
428 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Ibrutinib and Waldenstroms Macroglobulinemia
Ibrutinib and Waldenstroms Macroglobulinemia
341 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
MYD88 mutation and management of Waldenstroms Macroglobulinemia
MYD88 mutation and management of Waldenstroms Macroglobul...
271 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Panobinostat and other HDAC inhibitors in relapsed Multiple Myeloma
Panobinostat and other HDAC inhibitors in relapsed Multip...
245 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Loading